SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending as market participants analyze reports that GameStop is building a stake in the company, sparking intense community debate over the feasibility, financing, and potential dilution of a rumored acquisition. While some see a strategic fit for retail collectibles, others are skeptical of the deal's logic, leading to high options activity and significant volatility in eBay's share price.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena &gt; Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

CockCardano is gaining traction as investors highlight its unique integration of real-world revenue from a chicken wings business to fuel token buybacks and passive income. The community actively promotes the project's ecosystem, including its staking arena and meme-focused platforms, emphasizing a long-term holding strategy.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as shareholders react to the company's record cash pile and discussions surrounding succession, with many in the community debating the merits of long-term defensive positioning versus the missed opportunities of the recent market rally. While some investors remain confident in Greg Abels ability to manage capital, others are expressing frustration over stagnant performance and a perceived lack of aggressive acquisition or dividend strategy.

Twenty One Capital, Inc. is focused on Bitcoin-related business. It offers shareholders a differentiated opportunity to gain exposure to Bitcoin through the equity markets. The company was founded on March 7, 2025 and is headquartered in Austin, TX.

Twenty One Capital Inc. - Ordinary Shares- Class A

Twenty One Capital Inc

Twenty One Capital is generating significant market interest following its debut, with the community focused on its role as a major public Bitcoin treasury holder and its potential to integrate Strike's financial infrastructure. Investors are closely debating the company's valuation relative to its massive Bitcoin holdings, while monitoring leadership's strategic vision for scaling the business beyond a passive asset model.

Urban One, Inc. is a multi-media company, which engages in radio broadcasting that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment consists of all radio broadcast results of operations and low powered television operations. The Reach Media segment consists of the results of operations for the related activities and operations of the company’s syndicated shows. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One and CLEO TV operations. The company was founded by Catherine L. Hughes in 1980 and is headquartered in Silver Spring, MD.

Urban One Inc - Ordinary Shares - Class A

Urban One Inc

Urban One is gaining attention as investors speculate on potential price action heading into Juneteenth, a period that has historically seen significant volatility and volume for the stock. Community discussion is split between traders hunting for a repeat of past momentum spikes and those concerned about the company's recent filing delays and broader financial performance.

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company. It engages in developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. The company was founded on February 12, 2026 and is headquartered in Cambridge, MA.

Hemab Therapeutics Holdings Inc.

COAG is attracting significant retail interest as a high-volatility microcap momentum play, with traders closely monitoring the ticker as a potential breakout candidate among small-cap gainers.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network is trending as investors highlight its role in cross-chain automation and interoperability, with the community closely tracking recent exchange listings and growing holder counts. Enthusiasts are actively debating its technical potential against established projects, maintaining a bullish outlook while discussing the stock's consolidation patterns and future growth prospects.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is trending due to a sustained surge in trading volume and share price momentum, fueling community speculation about a potential buyout or major partnership. Investors are actively discussing the possibility of a strategic acquisition, despite the company's recent history of leadership turnover and cost-cutting measures.

Dumb SEND IT

$DSIT is driving significant community engagement as holders rally behind the project's active development, upcoming website launch, and aggressive airdrop incentives. Investors are debating the project's long-term utility and transparency while actively participating in 'Dumb SEND IT' campaigns to push the token toward new market cap milestones.

Dogelon Mars

Dogelon Mars is attracting significant community interest as investors actively debate growth potential, potential token burns, and the project's long-term viability. The conversation is driven by a mix of optimistic supporters aiming for broader adoption and critical voices questioning the coin's historical performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The open-label study evaluated Celcuity’s investigational gedatolisib in combination with fulvestrant, both with and without palbociclib.</li><li>Celcuity plans to submit the results to the FDA as part of a supplemental New Drug Application and to other regulators thereafter.</li><li>Celcuity has submitted an application already for gedatolisib in patients with some types of breast cancer, on which the agency will decide on July 17.&nbsp;</li></ul>Shares of Celcuity Inc. (CELC) jumped 14% after hours after the company said on Friday that its experimental cancer drug delivered a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with certain advanced breast cancers.The open-label study evaluated Celcuity’s investigational gedatolisib in combination with fulvestrant, both with and without palbociclib. Patients had progressed after prior treatment with a palbociclib plus an aromatase inhibitor.Both the gedatolisib triplet and doublet regimens outperformed the control arm, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival.Both gedatolisib regimens were generally well tolerated with manageable safety profiles, the company said. Detailed data will be presented on June 2 at the ASCO Annual Meeting in Chicago.“These positive topline results demonstrate the potential for gedatolisib to become a transformative new medicine for the treatment of patients with PIK3CA-mutant HR+/HER2- advanced breast cancer,” said Igor Gorbatchevsky, Celcuity’s chief medical officer.Celcuity plans to submit the results to the FDA as part of a supplemental New Drug Application and to other regulators thereafter.Celcuity has submitted an application already for gedatolisib in patients with some types of breast cancer, on which the agency will decide on July 17. The agency also granted priority review to the drug in the indication.<h2 class="st-heading-2">How Did CELC Retail Traders React?</h2>On Stocktwits, retail sentiment stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user applauded the trial data.<stembedurl>https://www.stocktwits.com/CharlieeMungerTWITS/message/652069628</stembedurl><a href="https://stocktwits.com/symbol/CELC">CELC stock</a> has rallied over 1000% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/vnda-stock-rises-after-hours-on-commercial-launch-of-motion-sickness-drug/cZQVZvNReet">VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Celcuity logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data

The company said that its experimental cancer drug delivered a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with certain advanced breast cancers.

Equity

The company said that its experimental cancer drug delivered a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with certain advanced breast cancers.


<ul class="summary-bullets"><li>The drug offers simple dosing with just one or two capsules a day taken approximately an hour before travel.</li><li>Patients can access Nereus at a cash-pay price of just $85 per dose, a meaningful discount from the standard list price of $255 per dose, the company said.</li><li>Vanda is also studying the drug in gatroparesis and the prevention of nausea and vomiting induced by GLP-1 drugs popularly used for weight loss and diabetes.</li></ul> Shares of Vanda Pharmaceuticals Inc. (VNDA) jumped 4% after hours on Friday after the company announced that its motion sickness drug is now commercially available across the U.S.The U.S. Food and Drug Administration approved Nereus for the prevention of vomiting induced by motion in adults in December. The FDA approval marked the first new pharmacologic treatment for motion sickness in more than 40 years.<h2 class="st-heading-2">Clinical Data For Nereus</h2>According to Vanda, motion sickness affects roughly 25 to 30% of adults during everyday travel by car, plane, or boat. Patients can now access the drug from the company’s dedicated direct-to-consumer portal for the drug or from retail pharmacies with a prescription. Patients can access Nereus at a cash-pay price of just $85 per dose, a meaningful discount from the standard list price of $255 per dose, the company said.The FDA approved Nereus following two late-stage trials conducted under real-world conditions on the open sea. In both trials, Nereus significantly prevented vomiting compared to placebo, confirming the drug's effectiveness. The drug offers simple dosing with just one or two capsules a day taken approximately an hour before travel.Vandas is also studying the drug in gatroparesis and the prevention of nausea and vomiting induced by GLP-1 drugs popularly used for weight loss and diabetes.<h2 class="st-heading-2">How Did VNDA Retail Traders React?</h2>On Stocktwits, retail sentiment around VNDA stock fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours while message volume remained at ‘normal’ levels.A Stocktwits user opined that the company could be bought out by GLP-1 drug makers like Eli Lilly, Novo Nordisk, or Pfizer in light of its efforts in treating the side effects of those drugs.<stembedurl>https://www.stocktwits.com/hktrader12/message/652070630</stembedurl><a href="https://stocktwits.com/symbol/VNDA">VNDA stock</a> has gained 58% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nspr-rallies-after-hours-on-fda-green-light-for-key-stroke-prevention-trial/cZQVklHReeA">NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Vanda Pharmaceuticals Inc. logo is pictured before a regular season Major League Baseball game between the Chicago White Sox and the Detroit Tigers on September 05, 2025. (Photo by Joseph Weiser/Icon Sportswire via Getty Images)

VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug

The U.S. Food and Drug Administration approved Nereus for the prevention of vomiting induced by motion in adults in December.

<ul class="summary-bullets"><li>Summit on Thursday reported a first-quarter 2026 net loss of $189.4 million, more than triple the $62.9 million loss a year earlier.</li><li>Piper Sandler lowered its price target on Summit to $16 from $17 and maintained a ‘Neutral’ rating on the shares.</li><li>The company’s interim update from its HARMONi-3 trial disappointed investors.&nbsp; Final data from the cohort remain on track for the second half of 2026.</li></ul> Shares of Summit Therapeutics Inc. (SMMT) closed 25% lower on Friday after the company reported a wider loss for the first quarter and an interim analysis update from its HARMONi-3 trial, prompting Piper Sandler to lower its price target on the stock.Piper Sandler lowered its price target on Summit to $16 from $17 and maintained a ‘Neutral’ rating on the shares.<h2 class="st-heading-2">Summit’s Q1 Earnings</h2>Summit on Thursday reported a first-quarter 2026 net loss of $189.4 million, more than triple the $62.9 million loss a year earlier, as the company ramps up spending on its lead asset ivonescimab in the treatment of non-small cell lung cancer (NSCLC).The company is studying Ivonescimab combined with chemotherapy in patients with first-line metastatic NSCLC in its HARMONi-3 trial, with two distinct cohorts to be analyzed separately for squamous tumors and non-squamous tumors.In squamous tumors, an independent Data Monitoring Committee completed a pre-specified interim progression-free survival analysis in Q2 2026 and recommended that the study continue as planned with no safety concerns, the company said. However, it did not hit the high statistical bar for early success/stop. Final data from the cohort remain on track for the second half of 2026.In the non-squamous tumors cohort, enrollment is expected to be completed by the end of Q2 2026, and data readout is targeted for the first half of 2027.According to Piper Sandler, investors are now questioning whether the impressive effect size seen in Akeso's HARMONi-6 can be replicated in Summit's global HARMONi-3.HARMONi-6 is a trial conducted in China and sponsored by Akeso, which evaluates ivonescimab in combination with platinum-based chemotherapy compared with the drug tislelizumab and platinum-based chemotherapy in non-small cell lung cancer.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around SMMT stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.A Stocktwits user dismissed the selloff as an overreaction.<stembedurl>https://www.stocktwits.com/northern18738901/message/652058452</stembedurl>Another echoed the sentiment, expressing optimism for the stock to rally back up over $18 in two weeks.<stembedurl>https://www.stocktwits.com/BobBijawklah/message/652053579</stembedurl><a href="https://stocktwits.com/symbol/SMMT">SMMT stock</a> has fallen 35% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nspr-rallies-after-hours-on-fda-green-light-for-key-stroke-prevention-trial/cZQVklHReeA">NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Summit Therapeutics company logo is seen on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

SMMT Stock Plunges On Wider Q1 Loss, Lung Cancer Clinical Trial Update

Summit on Thursday reported a first-quarter 2026 net loss of $189.4 million, more than triple the $62.9 million loss a year earlier.

<ul class="summary-bullets"><li>While durable responses were observed in select patients through extended follow-up, the overall magnitude and consistency of activity were not sufficient to support continued development relative to other pipeline programs, it said.&nbsp;</li><li>However, the experimental therapy demonstrated a differentiated tolerability profile with fewer gastrointestinal, dermatologic, and subcutaneous adverse events as compared to other drugs belonging to its category.&nbsp;</li><li>The company also clarified that the decision to discontinue JANX008 is program-specific and part of its efforts to prioritize parts of its portfolio.</li></ul>Shares of Janux Therapeutics, Inc. (JANX) edged up 1% after hours after the company said on Monday that it will discontinue development of its experimental program called JANX008 to focus its resources on its remaining pipeline.The company said that it came to the decision after completing early-stage trials across multiple solid tumor indications and an internal review of the data. While durable responses were observed in select patients through extended follow-up, the overall magnitude and consistency of activity were not sufficient to support continued development relative to other pipeline programs, it said.However, the experimental therapy demonstrated a differentiated tolerability profile with fewer gastrointestinal, dermatologic, and subcutaneous adverse events as compared to other drugs belonging to its category, the company said. Overall safety profile also allows for outpatient dosing, the company noted.The company also clarified that the decision to discontinue JANX008 is program-specific and part of its efforts to prioritize parts of its portfolio.“Our decision to discontinue JANX008 reflects the disciplined approach we take to advancing our pipeline,” said David Campbell, Ph.D., President and Chief Executive Officer of Janux. “We evaluate each program against a high bar for safety, activity, and differentiated profile. We prioritize resources toward programs that meet these criteria and offer opportunities to deliver best-in-class outcomes.”Janux is currently also evaluating other experimental drugs for the treatment of prostate cancer as well as autoimmune diseases. Earlier this month, the company said that it dosed the first participant in an early-stage study of JANX014, one of its candidates for prostate cancer.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around JANX fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.JANX stock has fallen 53% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/crmd-stock-jumps-as-antifungal-drug-clears-key-trial-for-2-billion-preventive-market/cZBNx6bRePY">CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Janux Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline

The company said that it came to the decision after completing early-stage trials across multiple solid tumor indications and an internal review of the data.

<ul class="summary-bullets"><li>BTIG added that updated Phase 1 PK/PD data also suggest ORKA-001 could enable once-yearly maintenance dosing, which the firm believes would be a first for any monoclonal antibody.</li><li>The firm raised its price target for Oruka by 94%, to $151 from $78, and maintained a ‘Buy’ rating on the stock.</li><li>Analysts at Guggenheim also hiked their price target for Oruka to $200 from $125, while adding that the company now has the potential to reach a peak of $7 billion in global sales for the psoriasis therapy.</li></ul>Shares of Oruka Therapeutics Inc. (ORKA) were on track for their best single-day gains in more than a month after the company announced interim results from a trial of its moderate-to-severe plaque psoriasis therapy.Oruka Therapeutics announced that 40 of the 63 participants in the EVERLAST-A Phase 2a trial of ORKA-001, a novel, half-life-extended IL-23p19 monoclonal antibody, met the primary endpoint.<a href="https://stocktwits.com/symbol/ORKA">Oruka Therapeutics shares</a> were up more than 20% in Monday’s opening trade.<h2 class="st-heading-2">BTIG Turns Bullish On Oruka</h2>According to TheFly, analysts at BTIG turned bullish on Oruka Therapeutics following the company’s interim trial results. The firm raised its price target for Oruka by 94%, to $151 from $78, and maintained a ‘Buy’ rating on the stock.BTIG added that updated Phase 1 PK/PD data also suggest ORKA-001 could enable once-yearly maintenance dosing, which the firm believes would be a first for any monoclonal antibody.BTIG stated that ORKA-001 has strong potential to become the preferred IL-23 inhibitor if approved, citing best-in-class efficacy and roughly one-fourth the maintenance injection burden of AbbVie’s (ABBV) Skyrizi.Analysts at Guggenheim also hiked their price target for Oruka to $200 from $125, while keeping a ‘Buy’ rating on the stock. The firm believes ORKA-001 has multi-billion-dollar blockbuster potential, adding that Oruka now has the potential to reach a peak of $7 billion in global sales for the psoriasis therapy.<h2 class="st-heading-2">Oruka’s Findings In The Trial</h2>Oruka stated that 64% of the participants in the trial achieved complete skin clearance in the 16th week.The company stated that key secondary endpoints were also strong, with 83% reaching PASI 90 during this period.In the placebo group, one of 21 participants met these endpoints, which it said was consistent with historical psoriasis trials.Oruka stated that cross-trial comparisons suggest ORKA-001 delivers higher skin clearance rates than other IL-23p19 inhibitors and ranks among the best reported in plaque psoriasis across all treatment types.The company stated that it plans to release longer-term EVERLAST-A data in the second half of 2026, including Week 28 results for all patients, along with a 52-week follow-up for a subset. Oruka also added that it will continue to advance the Phase 2b EVERLAST-B trial, with data expected in 2027.PASI refers to the Psoriasis Area and Severity Index. It quantifies the severity and extent of psoriasis symptoms across body regions. PASI 90 refers to a 90% or more improvement. Similarly, PASI 100 denotes a 100% improvement over baseline.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ORKA">Oruka Therapeutics</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels as of this writing.One bullish user believes ORKA stock could reach $200 per share soon.<stembedurl>https://stocktwits.com/Chiefstaff/message/651484000</stembedurl><a href="https://stocktwits.com/symbol/ORKA">ORKA stock</a> is up 172% year-to-date and 716% over the past 12 months. The S&amp;P Biotech ETF (XBI) is up 68% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 42%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/microsoft-loses-exclusive-license-openai-models-taps-anthropic-claude/cZBNAqiRePg">Microsoft Loses Exclusive Access To OpenAI Models In Partnership Reset Ahead Of Q3 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

“We are pleased to have settled our lawsuit with the United States Department of Justice,” the LYV said in a statement as its stock closed higher. 

ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94%

Oruka Therapeutics stated that 64% of the participants in the Phase 2a EVERLAST-A trial of ORKA-001 met the study’s primary endpoint.

<ul class="summary-bullets"><li>The company stated that 62% of the patients in the trial who received lonvo-z were entirely free of HAE attacks during the six-month evaluation period, compared to 11% of patients who received placebo.</li><li>Lonvo-z is a one-time treatment administered in an outpatient setting.</li><li>Intellia Therapeutics also stated that it has initiated a rolling Biologics License Application submission to the U.S. Food and Drug Administration.</li></ul>Shares of Intellia Therapeutics Inc. (NTLA) soared in Monday’s pre-market trade after the company reported positive Phase 3 trial results in its therapy for a rare genetic condition.<a href="https://stocktwits.com/symbol/NTLA">Intellia Therapeutics shares</a> were up more than 9% before the bell on Monday, on track for the biggest gains in this month so far. NTLA was the top trending ticker on the platform at the time of writing.<h2 class="st-heading-2">Rare Genetic Condition Trial Meets All Endpoints</h2>Intellia Therapeutics stated that its Phase 3 trial of lonvoculin ziclumeran (lonvo-z) met the primary and secondary endpoints, with favorable safety and tolerability.The Cambridge, Massachusetts-based biopharmaceutical company evaluated lonvo-z for the treatment of hereditary angioedema (HAE), a rare genetic condition characterized by recurrent, sometimes life-threatening episodes of swelling (angioedema) in different parts of the body. This includes the face, upper airway, abdomen, and extremities due to bradykinin overproduction.The company designed lonvo-z as a one-time treatment that is administered in an outpatient setting. Lonvo-Z is an in vivo CRISPR gene-editing candidate designed to disable the kallikrein B1 (KLKB1) gene, aiming to permanently reduce kallikrein and bradykinin levels.“For those patients who have spent years battling unpredictable breakthrough swelling attacks, anxiety about their next attack or the many burdens associated with chronic prophylactic treatment, lonvo-z represents a potential paradigm shift in treatment,” said Intellia Therapeutics CEO John Leonard.The company stated that 62% of the patients in the trial who received lonvo-z were entirely free of HAE attacks during the six-month evaluation period, compared to 11% of patients who received a placebo.<h2 class="st-heading-2">Intellia Submits Application For FDA Approval</h2>Intellia Therapeutics also stated that it has initiated a rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for approval.It is also preparing for a potential U.S. launch of lonvo-z in the first half of 2027.Intellia Therapeutics stated that it will present additional data at the 2026 European Academy of Allergy and Clinical Immunology Congress in June this year.The company said that one in 50,000 people is estimated to be affected by HAE.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/NTLA">Intellia Therapeutics</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.One user stated that gene editing is the future.<stembedurl>https://stocktwits.com/2h2guard/message/651485761</stembedurl>Another bullish user recommended investing now before it is too late for the perfect buying opportunity.<stembedurl>https://stocktwits.com/JuniorStocka/message/651485649</stembedurl><a href="https://stocktwits.com/symbol/NTLA">NTLA stock</a> is up 52% year-to-date and 67% over the past 12 months. The ARK Innovation ETF (ARKK) is up 53% over the past 12 months, while the S&amp;P Biotech ETF (XBI) is up 65%.The iShares Russell 2000 ETF (IWM) is up 43% during this period, while the Vanguard Small-Cap Growth Index Fund ETF Shares (VBK) is up 36%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/qcom-stock-highest-level-3-months-wall-street-not-bullish-q2-earnings/cZBNZwBRe2M">QCOM Stock On Track To Open At Highest Levels In 3 Months, But Wall Street Is Cautious Ahead Of Q2 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA. (Photo by: Spencer Grant/GHI/UCG/Universal Images Group via Getty Images)

NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late

Intellia Therapeutics stated that its Phase 3 trial of lonvoguran ziclumeran met the primary and secondary endpoints, with favorable safety and tolerability.

<ul class="summary-bullets"><li>If data from a third-stage trial is supportive, the company expects to submit an application to the U.S. Food and Drug Administration (FDA) seeking approval for the therapy in the second half of 2026.&nbsp;</li><li>The company will announce the data on Monday.&nbsp;</li><li>In addition to lonvoguran ziclumeran, Intellia is also developing another therapy called Nexiguran Ziclumeran (Nex-z) for Transthyretin (ATTR) Amyloidosis.</li></ul>Shares of Intellia Therapeutics (NTLA) jumped 22% after hours on Friday after the company said that it will announce clinical data from the late-stage trial of its experimental therapy lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday.Lonvo-z is designed to inactivate a gene in the liver, dramatically reducing or eliminating HAE attacks via a one-time treatment. Hereditary angioedema (HAE) is a rare, autosomal dominant genetic disorder causing recurrent, severe, non-itchy swelling in the limbs, face, intestinal tract, and airway.Intellia completed enrollment of 80 patients in the global study in September 2025, ahead of schedule. If data from the trial is supportive, the company expects to submit an application to the U.S. FDA seeking approval for the therapy in the second half of 2026, with a launch planned for the first half of 2027.In addition to lonvoguran ziclumeran, Intellia is also developing another therapy called Nexiguran Ziclumeran (Nex-z) for Transthyretin (ATTR) Amyloidosis. The U.S. Food and Drug Administration imposed a clinical hold on the company’s clinical trials in October after a patient experienced severe liver complications and subsequently died, but lifted the hold earlier this year, allowing the trials to proceed.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around NTLA stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels. &nbsp;A Stocktwits user highlighted that the data announcement is coming earlier than expected and wondered if the move signals confidence. In February, the company had pitched the data announcement for mid-2026.&nbsp; <stembedurl>https://www.stocktwits.com/Monkey7779192/message/651352863</stembedurl>Another user warned caution in light of the stock surge.<stembedurl>https://www.stocktwits.com/sister/message/651352429</stembedurl>A third user said that they have “a good feeling” about the upcoming readout.<stembedurl>https://www.stocktwits.com/Beyzade/message/651356875</stembedurl><a href="https://stocktwits.com/symbol/NTLA">NTLA stock </a>has gained 67% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ihrt-stock-soars-on-merger-talks-with-sirius-xm-report/cZBhkrJRecp">IHRT Stock Soars On Merger Talks With Sirius XM: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy 

Lonvo-z is designed to inactivate a gene in the liver, dramatically reducing or eliminating HAE attacks via a one-time treatment.

<ul class="summary-bullets"><li>FDA refused to approve Replimune’s melanoma drug RP1 for the second time earlier this month, citing insufficient data to provide “substantial evidence of effectiveness.”</li><li>Doctors also called for a change in leadership at the FDA over its decision not to approve Replimune’s RP1.&nbsp;</li><li>According to a report from Reuters, Health Secretary Robert F. Kennedy Jr. told a Senate hearing on Wednesday that he had little role in the FDA’s decision to reject RP1.</li></ul>Shares of Replimune (REPL) jumped 22% on Wednesday after doctors who treat melanoma expressed disappointment over the U.S. Food and Drug Administration’s rejection of the company’s experimental drug RP1.FDA refused to approve Replimune’s melanoma drug RP1 for the second time earlier this month, citing insufficient data to provide “substantial evidence of effectiveness” in the treatment of unresectable advanced cutaneous melanoma.Doctors, in an opinion piece <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/opinion/fda-rp1-replimune-melanoma-drug-rfk-jr-vinay-prasad-marty-makary-b8d666b2?mod&amp;#61;Searchresults&amp;pos&amp;#61;1&amp;page&amp;#61;1">published</a> in The Wall Street Journal, criticized the FDA’s decision, noting that the initial panel that reviewed RP1 had recommended approval, which was later overruled by the then-FDA biologics chief, Vinay Prasad.The second team that reviewed the drug also did not say that the drug was ineffective, instead saying that it is “unclear whether the drug was effective,” the doctors said. Melanoma doctors organized and sent a letter to the FDA imploring it to approve RP1, they noted, while adding that they weren't asked by the pharma industry to do it.“Denying patients a life-saving medicine for inexplicable reasons is the wrong kind of change. If Dr. Makary doesn’t understand that, the FDA needs a change in leadership,” the doctors said.<h2 class="st-heading-2">Kennedy Distances Self</h2>According to a report from <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/us-health-secretary-kennedy-distances-himself-fdas-replimune-cancer-drug-2026-04-22/">Reuters</a>, Health Secretary Robert F. Kennedy Jr. told a Senate hearing on Wednesday that he had little role in the FDA’s decision to reject R1.He, instead, said that the decision was in the hands of FDA Commissioner Marty Makary."This decision comes out of FDA, and we trust ​the process there,” Kennedy reportedly said.<h2 class="st-heading-2">Replimune’s Efforts With RP1 Approval</h2>In late July 2025, the FDA had issued a complete response letter regarding the company’s application for RP1 in combination with Nivolumab for the treatment of advanced melanoma.The agency said in the letter then that it is unable to approve the application in its present form, and indicated that the trial conducted by the company for the drug is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness. It further urged that the company conduct and provide the results from a fresh trial for further consideration.Replimune subsequently resubmitted its application in October with additional information and analyses, but no additional trial.Earlier this month, the FDA said that the revised application does not alter its initial conclusion of the ineffectiveness of the trials conducted by the company. The agency also noted that the members of the team who reviewed the resubmission were different from those who reviewed the initial application to maintain objectivity.Replimune can either resubmit or withdraw its application within a year.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around REPL stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed within ‘extremely low’ levels.A Stocktwits user opined that “REPL is done for the next two years” and added that the company needs a lifeline from another company.<stembedurl>https://www.stocktwits.com/CanaryMarketIntel/message/651056221</stembedurl>Another user reiterated confidence in the FDA’s decision to reject the drug.<stembedurl>https://www.stocktwits.com/PensionPulse/message/651038201</stembedurl>Another user, however, said that they are looking for 30X gains on REPL stock.<stembedurl>https://www.stocktwits.com/Rookie_investor/message/651040943</stembedurl><a href="https://stocktwits.com/symbol/REPL">REPL stock</a> has fallen 74% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ual-goes-silent-on-airline-merger-speculation-following-aal-snub/cZBBCayReb7">UAL Goes Silent On Airline Merger Speculation Following AAL Snub</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

REPL Ignites On Doctor Fury Against FDA’s Melanoma Drug Snub — Health Sec Steps Back

Doctors, in an opinion piece published on The Wall Street Journal, criticised the FDA’s decision, noting that the initial panel that reviewed RP1 recommended approval. 

Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?

<ul class="summary-bullets"><li>Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia cells from natural programmed cell death, making them more vulnerable.</li><li>Pharmacodynamic changes were observed in AML cells as early as eight hours after treatment and became more pronounced over time, the company noted.</li><li>Meanwhile, Sellas’s late-stage trial of its lead candidate GPS in Acute Myeloid Leukemia is advancing toward final analysis.</li></ul>Shares of Sellas Life Sciences Group Inc. (SLS) closed up 6% and edged up 2% after-hours on Friday, garnering heavy retail interest as investors anticipated upcoming data updates on its pipeline at the American Association for Cancer Research.According to Stocktwits platform data, retail chatter increased 36% over the past day, rising from ‘low’ to ‘normal’ levels.Sellas is slated to present preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center. Sellas will make its presentation on April 21.<h2 class="st-heading-2">Pipeline Optimism</h2>Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia (AML) cells from natural programmed cell death, making them more vulnerable. Pharmacodynamic changes were observed in AML cells as early as eight hours after treatment and became more pronounced over time, the company noted.“The ability to lower apoptotic threshold in AML cells by suppressing key survival pathways and enhancing potency with repeated exposure further supports the development of SLS009, including in combination regimens,” said Dragan Cicic, Chief Development Officer of SELLAS.Sellas’s lead candidate, GPS, meanwhile, is being evaluated for its potential as a monotherapy and in combination with other therapies to address a broad spectrum of blood malignancies and solid tumor indications.The company’s late-stage trial of GPS in Acute Myeloid Leukemia is advancing toward final analysis. The final analysis is slated for when the company records the 80th patient death in the trial. In December, the company announced that 72 events had been completed and it will announce when the 80th event occurs. With event-driven trials like Sellas’s, the delay highlights longer survival, indicating potential for the therapy.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around SLS stock rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours.A Stocktwits user said that the stock has two near-term catalysts in terms of the upcoming conference and update on the GPS program in AML.<stembedurl>https://www.stocktwits.com/55X_ROI_Q1_2026/message/650652881</stembedurl>Yet another sounded optimistic for the company’s pipeline, highlighting the many designations granted to Sellas’s experimental therapies.<stembedurl>https://www.stocktwits.com/gata2016/message/650649884</stembedurl><a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has nearly quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-on-track-for-best-day-in-nearly-16-months-whats-driving-the-rally/cZJyGq6RIUn">CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Last week, Baird maintained AYI’s ‘neutral’ rating but cut price target to $320 from $375. (Representative image: Getty Images)

SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy

Sellas is slated to announce preclinical data on its experimental cancer therapy SLS009 in a poster session at the conference which started on April 17 and is slated to go till April 22 at the San Diego Convention Center.

Current Price	$130.42
Prev Close	$131.33
Open	$130.62
Dividend Yield	N/A
50-Day Moving Average	$128.01
Beta	N/A
Avg. Volume	8.43M
PE Ratio	N/A

52-Week High	$139.19
52-Week Low	$75.68
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

XBI
SPDR S&P Biotech ETF

Feed

News

Sentiment

Fundamentals

Info

Latest XBI News

XBISPDR S&P Biotech ETF